Xiap is a predictor of Cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Yang, Xi Hu ^a,b   Feng, Zhi En ^a,b   Yan, Ming ^a,b   Hanada, Sayaka ^c   Zuo, Hui ^c   Yang, Cheng Zhe ^a,b   Han, Ze Guan ^a,b   Guo, Wei ^a   Chen, Wan Tao ^a,b   Zhang, Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Stomatology   (China)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MESSENGER RNA; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; TREATMENT OUTCOME; UPREGULATION; CANCER STAGING; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84863233878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031601     Document Type: Article

References (25)

1. Parkin DM, Pisani P, Ferlay J, (1999) Global cancer statistics. CA Cancer J Clin 49: 33-64, 31.
2. Gourin CG, Podolsky RH, (2006) Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope 116: 1093-1106.
3. Hauswald H, Simon C, Hecht S, Debus J, Lindel K, (2011) Long-term outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol 6: 70.
4. Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, et al. (2011) Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer.
5. Reed JC, (2001) The Survivin saga goes in vivo. J Clin Invest 108: 965-969.
6. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, et al. (2008) IAP-targeted therapies for cancer. Oncogene 27: 6252-6275.
7. Devi GR, (2004) XIAP as target for therapeutic apoptosis in prostate cancer. Drug News Perspect 17: 127-134.
8. Deveraux QL, Takahashi R, Salvesen GS, Reed JC, (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300-304.
9. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, et al. (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223.
10. Holcik M, Gibson H, Korneluk RG, (2001) XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6: 253-261.
11. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE, (1998) The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259.
12. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, et al. (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25: 3719-3725.
13. Hitt R, Ciruelos E, Amador ML, Benito A, Sanchez JJ, et al. (2005) Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 41: 453-460.
14. Amantana A, London CA, Iversen PL, Devi GR, (2004) X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3: 699-707.
15. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, et al. (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9: 2826-2836.
16. Li Y, Jian Z, Xia K, Li X, Lv X, et al. (2006) XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 32: 288-296.
17. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, et al. (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131: 669-681.
18. Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, et al. (2008) Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 111: 369-375.
19. Xiang G, Wen X, Wang H, Chen K, Liu H, (2009) Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol 100: 708-712.
20. Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, et al. (2007) Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 30: 919-925.
21. Cao W, Younis RH, Li J, Chen H, Xia R, et al. (2011) EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia. Cancer Prev Res (Phila).
22. Petak I, Schwab R, Orfi L, Kopper L, Keri G, (2010) Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 9: 523-535.
23. Cardinali M, Pietraszkiewicz H, Ensley JF, Robbins KC, (1995) Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. International journal of cancer Journal international du cancer 61: 98-103.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
25. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.